. Author manuscript; available in PMC: 2018 Oct 1.

Published in final edited form as: J Steroid Biochem Mol Biol. 2016 Sep 17;173:69–74. doi: 10.1016/j.jsbmb.2016.09.015

Table 1.

Gemini compound BXL0124 inhibits MCF10DCIS human breast cancer xenograft tumor growth in SCID mice.

Group	No. animals	Average Body Weight at Day 3 (g)	Average Body Weight at Autopsy (g)	Final Tumor Volume at Autopsy (mm³)^§	Final Tumor Weight (g)^‡^§	Serum Calcium (mg/dl)
Control	9	20.3 ± 1.7	21.9 ± 1.7	322.4 ± 214.4	0.29 ± 0.18	9.03 ± 0.45
BXL0097	8	20.2 ± 1.3	22.4 ± 1.7	285.3 ± 202.7	0.33 ± 0.22	ND
BXL0124	8	20.4 ± 1.3	21.4 ± 2.5	96.1 ± 81.0^**	0.11 ± 0.09^**	9.56 ± 0.65

MCF10DCIS.com cells (1 million cells per mouse) were injected into the mammary fat pad of female SCID mice. Three days after tumor cells injection, mice received daily i.p. injection of vehicle or Gemini vitamin D compounds (0.1 µg/kg body weight). Mice were sacrificed at day 34.

^§

Data are expressed as mean ± S.D.

^**

(p<0.01 by the Student’s t-test).

^‡

Average tumor burden in each mouse at autopsy. ND not determined.